Cidara Therapeutics announces participation in investor conferences; highlights DFC therapeutic development and recent FDA designations.
Quiver AI Summary
Cidara Therapeutics, Inc., a biotechnology company focused on developing drug-Fc conjugate therapeutics using its Cloudbreak® platform, announced its participation in two upcoming investor conferences in September 2025. The first conference is the H.C. Wainwright 27th Annual Global Investment Conference, where they will present on September 8 at 4:00 PM ET, and the second is the Morgan Stanley 23rd Annual Global Healthcare Conference, featuring a fireside chat on September 9 at 7:00 AM ET. In addition, Cidara will engage in one-on-one investor meetings during these events. The company is progressing its lead DFC candidate, CD388, which targets seasonal and pandemic influenza, and has recently reported positive results from a Phase 2b trial and received Fast Track Designation from the FDA. Cidara is also advancing additional DFCs for oncology, including a candidate targeting CD73 in solid tumors.
Potential Positives
- Cidara Therapeutics will be participating in two prominent investor conferences, enhancing its visibility and potential investor interest in its innovative drug development.
- The company’s lead DFC candidate, CD388, has received Fast Track Designation from the FDA, indicating a favorable regulatory standing that could accelerate its development and approval process.
- Positive top-line results from the Phase 2b NAVIGATE trial for CD388 were announced, indicating promising efficacy and potential for future market success.
- Cidara has secured investigational new drug application clearance for CBO421, demonstrating the company’s ability to advance its oncology pipeline and diversify its therapeutic offerings.
Potential Negatives
- None
FAQ
What investor conferences will Cidara Therapeutics attend in September 2025?
Cidara Therapeutics will attend the H.C. Wainwright and Morgan Stanley conferences on September 8 and 9, 2025.
What is the format of Cidara’s presentations at these conferences?
Cidara will offer a corporate presentation at the H.C. Wainwright Conference and a fireside chat at the Morgan Stanley Conference.
What is Cidara Therapeutics known for?
Cidara Therapeutics is known for developing drug-Fc conjugates (DFCs) using its proprietary Cloudbreak® platform.
What is Cidara’s lead DFC candidate?
This company’s lead DFC candidate is CD388, designed for long-acting antiviral prevention of influenza.
What recent achievements has Cidara Therapeutics accomplished?
In June 2023, CD388 received Fast Track Designation from the FDA, with positive Phase 2b trial results announced in June 2025.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CDTX Insider Trading Activity
$CDTX insiders have traded $CDTX stock on the open market 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CDTX stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA purchased 2,272,727 shares for an estimated $99,999,988
- CHRYSA MINEO has made 2 purchases buying 3,320 shares for an estimated $73,895 and 0 sales.
- LESLIE TARI (CHIEF SCIENTIFIC OFFICER) sold 1,773 shares for an estimated $38,939
- SHANE WARD (COO & CLO) sold 1,664 shares for an estimated $36,542
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CDTX Hedge Fund Activity
We have seen 96 institutional investors add shares of $CDTX stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 2,272,727 shares (+208.0%) to their portfolio in Q2 2025, for an estimated $110,704,532
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC added 1,797,600 shares (+255.7%) to their portfolio in Q2 2025, for an estimated $87,561,096
- POINT72 ASSET MANAGEMENT, L.P. added 1,414,075 shares (+1242.0%) to their portfolio in Q2 2025, for an estimated $68,879,593
- BLACKROCK, INC. added 1,054,772 shares (+1994.0%) to their portfolio in Q2 2025, for an estimated $51,377,944
- MORGAN STANLEY added 875,198 shares (+10651.1%) to their portfolio in Q2 2025, for an estimated $42,630,894
- DARWIN GLOBAL MANAGEMENT, LTD. added 768,424 shares (+inf%) to their portfolio in Q2 2025, for an estimated $37,429,933
- VIVO CAPITAL, LLC added 627,149 shares (+91.7%) to their portfolio in Q2 2025, for an estimated $30,548,427
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CDTX Analyst Ratings
Wall Street analysts have issued reports on $CDTX in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 08/08/2025
- RBC Capital issued a "Outperform" rating on 06/24/2025
- Guggenheim issued a "Buy" rating on 06/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/24/2025
- WBB Securities issued a "Strong Buy" rating on 06/23/2025
- Needham issued a "Buy" rating on 06/23/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/10/2025
To track analyst ratings and price targets for $CDTX, check out Quiver Quantitative's $CDTX forecast page.
$CDTX Price Targets
Multiple analysts have issued price targets for $CDTX recently. We have seen 10 analysts offer price targets for $CDTX in the last 6 months, with a median target of $59.5.
Here are some recent targets:
- Roy Buchanan from JMP Securities set a target price of $66.0 on 08/08/2025
- Joseph Stringer from Needham set a target price of $74.0 on 08/08/2025
- Sara Nik from HC Wainwright & Co. set a target price of $74.0 on 08/08/2025
- Brian Abrahams from RBC Capital set a target price of $75.0 on 06/24/2025
- Seamus Fernandez from Guggenheim set a target price of $68.0 on 06/24/2025
- Steve Brozak from WBB Securities set a target price of $45.0 on 06/23/2025
- Roy Buchanan from Citizens Capital Markets set a target price of $46.0 on 03/12/2025
Full Release
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences.
Details are as follows:
Event
: H.C. Wainwright 27
th
Annual Global Investment Conference
Date
: September 8, 2025
Time:
4:00 PM ET
Format:
Corporate Presentation
Event
: Morgan Stanley 23
rd
Annual Global Healthcare Conference
Date
: September 9, 2025
Time:
7:00 AM ET
Format:
Fireside Chat
Cidara will also participate in one-on-one investor meetings during the conferences.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak
®
platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit
www.cidara.com
.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
[email protected]
